🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are increasing globally, with estimates suggesting in excess of 82 million infections per year. Particularly high rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

According to findings published in a major medical journal, zoliflodacin eradicated the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which combines a dual-drug approach. The study involved hundreds of participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Having a easy-to-administer therapy like this is hailed as a "critical tool" for managing the epidemic. This is considered vital to alleviate the strain of the disease for people and to stop the proliferation of untreatable gonorrhoea globally.